Engineered Islet Cell Dosing for Immune-Evasive Diabetes Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for beta cell disorders, such as Type I diabetes, often require high doses of exogenous insulin and suffer from immune rejection and adverse side effects, limiting their efficacy and patient outcomes.
Innovation Solution
Administering engineered hypoimmunogenic islet cells, modified to reduce MHC class I and II expression and increase CD47 expression, via intramuscular injection, at specific doses ranging from 1×10^7 to 3×10^8 cells or 6,500 to 24,000 islet equivalents per kilogram of body weight, to promote engraftment and insulin production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high doses of exogenous insulin are administered to treat beta cell disorders, then glycemic control is improved, but adverse side effects increase and patient outcomes are limited
Solution Approach 1:
The patent employs engineered beta cells that autonomously sense glucose levels and secrete insulin in a physiologically appropriate manner, eliminating the need for external insulin administration. The hypoimmunogenic modifications enable these cells to self-protect from immune rejection while maintaining their endocrine function, achieving long-term glycemic control without the adverse effects associated with exogenous insulin therapy
Solution Approach 2:
The patent fundamentally changes the therapeutic approach by transitioning from administering exogenous insulin (a chemical parameter change) to transplanting engineered living cells that produce insulin endogenously. The hypoimmunogenic modifications alter the immunological parameters of the beta cells, reducing MHC class I and II expression and increasing CD47 expression, which changes the immune recognition parameters and enables long-term engraftment without severe immune-mediated adverse effects
2Reliability
If islet cell transplantation is performed to restore endogenous insulin production, then insulin independence is achieved, but immune rejection occurs
Solution Approach 1:
The patent applies multiple genetic parameter changes to the beta cells: reducing MHC class I expression by 50-90%, reducing MHC class II expression by 50-90%, and increasing CD47 expression by 2-10 fold. These parameter changes collectively modify the immunogenicity profile of the transplanted cells, enabling them to evade immune detection and rejection while maintaining their insulin-producing function
Solution Approach 2:
The patent creates composite engineered beta cells that combine multiple genetic modifications within a single cell type. The cells integrate hypoimmunogenic modifications (reduced MHC I and II, increased CD47) with preserved endocrine function, creating a composite cellular product that simultaneously achieves immune evasion and physiological insulin secretion
3Ease of operation
If standard islet cell dosing is used for transplantation, then treatment is simplified, but engraftment efficiency and long-term function are insufficient
Solution Approach 1:
The patent establishes specific dosing parameters based on recipient weight and disease severity: administering 1×10^7 to 3×10^8 engineered beta cells per recipient, or 1.25×10^5 to 1.2×10^7 cells per kilogram body weight, or 6,500 to 600,000 islet equivalents, or 80 to 24,000 islet equivalents per kilogram. These optimized parameters ensure sufficient engraftment for long-term function while maintaining practical administration protocols
Data Source
AI summary
Provided herein are methods of dosing engineered islet cells that include functional modified beta cell containing one or more modifications, such as genetic modifications. In some embodiments, the engineered islets are hypoimmunogenic cells. In some embodiments, the one or more modifications reduce or eliminate expression of one or more MHC class I and/or MHC class II human leukocyte antigens and also increase expression of one or more tolerogenic factors, such as CD47. In some embodiments, the subject has a beta cell related disorder, such as diabetes (e.g. Type I diabetes).